330 related articles for article (PubMed ID: 29757772)
1. Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
Schoepfer A; Vavricka SR; Brüngger B; Reich O; Blozik E; Bähler C
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):868-875. PubMed ID: 29757772
[TBL] [Abstract][Full Text] [Related]
2. Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study.
Sulz MC; Siebert U; Arvandi M; Gothe RM; Wurm J; von Känel R; Vavricka SR; Meyenberger C; Sagmeister M;
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):790-7. PubMed ID: 23571609
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients.
Simian D; Fluxá D; Flores L; Lubascher J; Ibáñez P; Figueroa C; Kronberg U; Acuña R; Moreno M; Quera R
World J Gastroenterol; 2016 Jun; 22(22):5267-75. PubMed ID: 27298570
[TBL] [Abstract][Full Text] [Related]
4. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
5. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
[TBL] [Abstract][Full Text] [Related]
6. Clostridium difficile co-infection in inflammatory bowel disease is associated with significantly increased in-hospital mortality.
Rezapour M; Galoosian A; Liu B; Bhuket T; Wong RJ
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1041-1046. PubMed ID: 29894325
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
[TBL] [Abstract][Full Text] [Related]
8. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
Fraga M; Fournier N; Safroneeva E; Pittet V; Godat S; Straumann A; Nydegger A; Vavricka SR; Moradpour D; Schoepfer AM;
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):91-97. PubMed ID: 27622999
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of intestinal complications in inflammatory bowel disease: a comparison between paediatric-onset and adult-onset patients.
Herzog D; Fournier N; Buehr P; Rueger V; Koller R; Heyland K; Nydegger A; Braegger CP;
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):926-931. PubMed ID: 28471820
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
11. Similar clinical characteristics of familial and sporadic inflammatory bowel disease in South Korea.
Chung SH; Park SJ; Lee HS; Hong SP; Cheon JH; Kim TI; Kim WH
World J Gastroenterol; 2014 Dec; 20(45):17120-6. PubMed ID: 25493025
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
Everhov ÅH; Halfvarson J; Myrelid P; Sachs MC; Nordenvall C; Söderling J; Ekbom A; Neovius M; Ludvigsson JF; Askling J; Olén O
Gastroenterology; 2018 Feb; 154(3):518-528.e15. PubMed ID: 29102619
[TBL] [Abstract][Full Text] [Related]
13. Health care costs associated with Australian tertiary inflammatory bowel disease care.
Jackson B; Con D; Ma R; Gorelik A; Liew D; De Cruz P
Scand J Gastroenterol; 2017 Aug; 52(8):851-856. PubMed ID: 28509590
[TBL] [Abstract][Full Text] [Related]
14. Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.
Taxonera C; Olivares D; Mendoza JL; Díaz-Rubio M; Rey E
World J Gastroenterol; 2014 Jul; 20(27):9170-7. PubMed ID: 25083091
[TBL] [Abstract][Full Text] [Related]
15. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.
Kappelman MD; Rifas-Shiman SL; Porter CQ; Ollendorf DA; Sandler RS; Galanko JA; Finkelstein JA
Gastroenterology; 2008 Dec; 135(6):1907-13. PubMed ID: 18854185
[TBL] [Abstract][Full Text] [Related]
16. Medical resource utilization and associated costs in patients with ulcerative colitis in the UK: a chart review analysis.
Bodger K; Yen L; Szende A; Sharma G; Chen YJ; McDermott J; Hodgkins P
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):213-21. PubMed ID: 24145865
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
18. Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden.
Khalili H; Everhov ÅH; Halfvarson J; Ludvigsson JF; Askling J; Myrelid P; Söderling J; Olen O; Neovius M;
Aliment Pharmacol Ther; 2020 Aug; 52(4):655-668. PubMed ID: 32902894
[TBL] [Abstract][Full Text] [Related]
19. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
Rubin DT; Mody R; Davis KL; Wang CC
Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
[TBL] [Abstract][Full Text] [Related]
20. Direct medical cost of managing IBD patients: a Canadian population-based study.
Bernstein CN; Longobardi T; Finlayson G; Blanchard JF
Inflamm Bowel Dis; 2012 Aug; 18(8):1498-508. PubMed ID: 22109958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
